« Back
Home /
Chikusetsusaponin Iva

Chikusetsusaponin Iva

Item no.	HY-N0818-10mg
Manufacturer	MedChem Express
CASRN	51415-02-2
Amount	10 mg
Quantity options	10 mM/1 mL 10 mg 1 mg 5 mg
Category	Neuroscience Metabolism Diabetes Glucose Homeostasis Cholesterol & Lipid Metabolism Regulation of Appetite Neural Signaling Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.95
Citations	[1]Cui J, et al. Insulinotropic effect of Chikusetsu saponin IVa in diabetic rats and pancreatic β-cells. J Ethnopharmacol. 2015 Apr 22;164:334-9.\|[2]Li Y, et al. Chikusetsu saponin IVa regulates glucose uptake and fatty acid oxidation: implications in antihyperglycemic and hypolipidemic effects. J Pharm Pharmacol. 2015 Jul;67(7):997-1007.\|[3]Dahmer T, et al. Antithrombotic effect of chikusetsusaponin IVa isolated from Ilex paraguariensis (Maté). J Med Food. 2012 Dec;15(12):1073-80.\|[4]Xu G, et al. Inhibition of chikusetsusaponin IVa on inflammatory responses in RAW264.7 cell line via MAPK pathway. Z Naturforsch C J Biosci. 2020 Sep 28;76(3-4):103-110. \|[5]Dai Q, et al. Chikusetsusaponin IVa Targets Nrf2 to Inhibit H9N2 Avian Influenza Virus Infection. Pharmacognosy Magazine, 2024: 09731296241277316.\|[6]Wang H, et al. Inhibitory effects of Chikusetsusaponin IVa on lipopolysaccharide-induced pro-inflammatory responses in THP-1 cells. Int J Immunopathol Pharmacol. 2015 Sep;28(3):308-17.\|[7]Gao K, et al. Chikusetsusaponin IVa targeted YAP as an inhibitor to attenuate liver fibrosis and hepatic stellate cell activation. Chin Med. 2025 Mar 17;20(1):36. \|[8]Guo X, et al. Anti-inflammatory and osteoprotective effects of Chikusetsusaponin Ⅳa on rheumatoid arthritis via the JAK/STAT signaling pathway. Phytomedicine. 2021 Dec;93:153801. \|[9]Liu YW, et al. Identification of chikusetsusaponin IVa as a novel lysine-specific demethylase 1 inhibitor that ameliorates high fat diet-induced MASLD in mice. Acta Pharmacol Sin. 2025 Mar;46(3):632-652. \|[10]Xu G, Lei H, Yuan Q, Chen H, Su J. Inhibition of chikusetsusaponin IVa on inflammatory responses in RAW264.7 cell line via MAPK pathway. Z Naturforsch C J Biosci. 2020 Sep 28;76(3-4):103-110.
Smiles	O=C([C@]1(CCC(C)(C)C2)[C@]2([H])C3=CC[C@@]4([H])[C@@](C)(CC[C@]5([H])[C@@]4(CC[C@H](O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6C(O)=O)C5(C)C)C)[C@]3(C)CC1)O[C@@H]([C@@H]([C@@H](O)[C@@H]7O)O)O[C@@H]7CO
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Calenduloside F
Shipping Condition	Room temperature
Available
Manufacturer - Type	Natural Products
Manufacturer - Targets	Keap1-Nrf2
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	794.97
Product Description	Chikusetsusaponin IVa is an orally active protein kinase activator. Chikusetsusaponin IVa binds to YAP with a KD value of 0.388 mM. Chikusetsusaponin IVa reduces inflammatory mediators (IL-6, IL-10, COX-2) expression, NO production, promotes ROS generation, induces Apoptosis, inhibits MAPK, TAZ, and regulates Nrf2, JAK/STAT. Chikusetsusaponin Iva has anti-H9N2 AIV and anti-endometrial cancer activities. Chikusetsusaponin Iva shows anti-inflammatory, hepatoprotective and osteoprotective effects[1][2][3][4][5][6][7][8][9][10].
Manufacturer - Research Area	Cancer; Infection; Endocrinology; Metabolic Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	NF-κB
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-N0818-10mg-safety-datasheet.pdf